Objective: To describe a set of tumor characteristics, prognosis and course of pregnancy in patients diagnosed with pregnancy-associated breast cancer (PABC). Methods. Retrospective cohort study of PABC young women. The histological profile, survival and pregnancy outcomes were assessed. Nonparametric tests, Fisher s exact test, Kaplan-Meier method, Cox regression and multivariate logistic regression were used for statistical analyses. Results. We assessed 16 PABC patients. All women self-palpated a breast mass, the women ≤ 35 years of age were diagnosed with unfavorable characteristics: advanced stage (88.8%), positive clinically lymph nodes (100%), high grade (55.5%), ER-negative (77.8%) and high-risk Nottingham prognostic index (66.7%). Seven deaths were observed with a median follow-up for overall survival (OS) of 64.5 months (range: 15-90). The 5-year OS rates were worse for patients with pathological lymph nodes > 4 (25%; p = 0.001) and with ER-negative disease (50%; p = 0.646). In our multivariate analysis, the nodal involvement was the only predictor associated to a worse OS (hazard radtio = 1.4, 90% confidence interval [CI]: 1.14 to 1.8). The following risk factors could influence in the risk of a preterm birth: mother s older age, gestational age at diagnosis and the chemotherapy during pregnancy, but their adjusted ORs of .61 (90% CI: 0.34 to 1), .80 (90% CI: 0.66 to 0.9) and .01 (90% CI: 0.00 to 0.9), respectively did not support statistically such an effect. Most cases of cases (77.7%) exposed to chemotherapy during pregnancy got a live term birth. Conclusion. Our findings described a more aggressive histological profile for youngest pregnant women coupled the delayed diagnosis might explain the high-risk of death. Simultaneous management of breast cancer and pregnancy was feasible.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institucional Review Board of: Hospital de Especialidades del Centro Medico de la Raza whether ethical approval was given with the number R-2005-3504-23.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors